Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
Recruiting now · Not applicable
Conditions studied: Pancreatic Cancer Non-resectable
In brief
The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.
Key facts
- Study ID
- NCT05424159
- Run by
- Shanghai Proton and Heavy Ion Center
- People needed
- 48
- Starts
- 2022-07-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2023-12-07
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have the ability to sign the written informed consent;
- Ductal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;
- Distant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC/UICC Version 8);
- The maximum diameter of pancreatic primary lesion and positive lymph node ≤7cm;
- Pancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);
- Eastern Cooperative Oncology Group (ECOG) performance score 0-1;
- Adequate bone marrow function (neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥10.0g/dL);
- Adequate liver function (total bilirubin <1.5 times the upper limit of normal value, aminotransferase <2.5 times the upper limit of normal value);
- Adequate renal function (serum creatinine <2mg/dL, or creatinine clearance >50mL/min).
You may not qualify if…
- Multiple primary pancreatic lesions (>1);
- Tumor invaded the adjacent digestive tract;
- Radiation therapy history;
- Other local treatments history for pancreatic cancer, such as HIFU and irreversible electroporation;
- The irradiation dose of organs at risk cannot reach the dose constraint;
- Other malignant tumors history;
- Inability to understand the purpose of treatment or unwillingness/inability to sign informed consent.
Where it is running
- Shanghai Proton and Heavy Ion Center — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.